Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial
Ehab Bakbak(The University of Queensland), Subodh Verma(St. Michael's Hospital), Deepak L. Bhatt(Mount Sinai Hospital), C. David Mazer(St. Michael's Hospital), Basel Bari(Custom Security Industries (Canada)), Hwee Teoh(St. Michael's Hospital), Aishwarya Krishnaraj(St. Michael's Hospital), Yi Pan(Shanghai Jiao Tong University), Elizabeth J. Fry, David A. Hess(Western University), Brady Park(St. Michael's Hospital), Daniella C. Terenzi(St. Michael's Hospital), Lawrence A. Leiter(St. Michael's Hospital), Adrian Quan(St. Michael's Hospital), Kristin A Terenzi, Asaad I. Bakbak(Lakeridge Health), Pankaj Puar(St. Michael's Hospital), Tayyab Khan(Western University), Ori D. Rotstein(St. Michael's Hospital)
Cited by 6
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k